Why overall survival and not progression free survival improves in era of program death inhibitors

Reyad Dada
  • Journal of Oncology Pharmacy Practice, May 2017, SAGE Publications
  • DOI: 10.1177/1078155217712402

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1177/1078155217712402

The following have contributed to this page: Reyad Dada

In partnership with: